BioWorld

Sep. 8, 2010

FDA Panel Backs Forest Antibiotic for CABP, cSSSI

Roche, reMYND in Pact to Develop PD, AD Drugs

Idenix Stock Plummets 47% on Negative HCV Drug Data

Shares in Idenix Pharmaceuticals Inc. sank 47 percent as the FDA placed a clinical hold on studies of IDX184 and IDX320 for hepatitis C virus due to elevated liver enzymes in three healthy volunteers. (BioWorld Today) Read More

Obama Seeking to Boost, Solidify R&D Tax Credit

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld

Sep. 8, 2010

FDA Panel Backs Forest Antibiotic for CABP, cSSSI

Roche, reMYND in Pact to Develop PD, AD Drugs

Stock Movers

Clinic Roundup

Financings Roundup

Other News To Note

Idenix Stock Plummets 47% on Negative HCV Drug Data

Obama Seeking to Boost, Solidify R&D Tax Credit

Today's news in brief

Today's news in brief

Second insulin receptor offers new therapeutic avenues

Mechanism underlying so-called idiopathic autism inception unveiled

Drug duo to Repare lack in gyno cancers? Phase I shows promise